GSK4418959 + PD-1 inhibitor
Phase 1/2Active 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms, Colorectal
Conditions
Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
Trial Timeline
Dec 13, 2024 → Jun 22, 2026
NCT ID
NCT06710847About GSK4418959 + PD-1 inhibitor
GSK4418959 + PD-1 inhibitor is a phase 1/2 stage product being developed by IDEAYA Biosciences for Neoplasms, Colorectal. The current trial status is active. This product is registered under clinical trial identifier NCT06710847. Target conditions include Neoplasms, Colorectal, Solid Tumor, Colon Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06710847 | Phase 1/2 | Active |
Competing Products
20 competing products in Neoplasms, Colorectal
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AB0024 | Gilead Sciences | Phase 1 | 32 |
| TTI-237 | Pfizer | Phase 1 | 32 |
| 852A | Pfizer | Phase 1 | 32 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| IMC-3C5 | Eli Lilly | Phase 1 | 33 |
| LY3295668 | Eli Lilly | Phase 1/2 | 41 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| enzastaurin | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Darolutamide + LHRH agonist/antagonist | Eli Lilly | Phase 1 | 33 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 52 |
| LY4337713 | Eli Lilly | Phase 1 | 33 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant | Eli Lilly | Phase 3 | 77 |
| VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg | Vincerx Pharma | Phase 1 | 25 |
| VIP236 (Q3W) + VIP236 (Q2W) | Vincerx Pharma | Phase 1 | 25 |
| GEMZAR + ALIMTA | Eli Lilly | Phase 3 | 77 |